Street view: AbbVie's immunology strength fuels long-term growth optimism
ABBV•AbbVie raised its annual profit forecast after demand for newer immunology and brain disease drugs helped it beat Wall Street's third-quarter expectations. Analysts cited Skyrizi, pipeline progress and commercial momentum as growth drivers, with the median price target at $301.50.
1. Analysts see growth drivers
Morgan Stanley said Skyrizi growth and combination therapies for inflammatory bowel disease will be key to AbbVie's 2027 performance. J.P. Morgan cited the company's core drivers and immunology pipeline as supporting revenue growth visibility into the 2030s.
2. Commercial momentum
Guggenheim said healthy product demand is expected to carry through the fourth quarter and into 2027. Bernstein said AbbVie's pipeline is becoming more interesting, particularly through efforts to expand its immunology franchise and opportunities in oncology. The median price target from 32 brokerages is $301.50, and the average rating is “buy.”
